Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
(Incorporated in the Cayman Islands with limited liability)
China NT Pharma Group Company Limited (the "Company") and its subsidiaries (collectively, the "Group") are pleased to announce that the Company successfully paid in full for the third installment of acquisition in relation to Miacalcic Injectable for US$50,000,000 on 15 December 2016 with an aggregate amount of US$100,000,000 for the payment of acquisition have been made. From the date of settlement in relation to Miacalcic Injectable on 7 July 2016 to the date of this announcement, the net profit of Miacalcic Injectable has all been transferred from Novartis to the Company, and the revenue and net profit attributable to Miacalcic Injectable in 2017 and subsequent years thereafter will both be consolidated into the accounts of the Company, which in turn will bring significant growth to the future revenue and profitability of the Company.
In addition, the progress of transfer of related assets under Miacalcic Injectable has been satisfactorily made with the listing permit of Switzerland was successfully transferred to an agent permit holder of the Company on 1 December 2016.
Miacalcic (a product name of salmon calcitonin) is a renowned international orthopedic brand name, which is mainly used for the treatment of osteoporosis, Paget's disease of bone and hypercalcemia. It shows a long-term stability on commercial sales with a global sales network. The acquisition of Miacalcic by the Company primarily covers an array of countries and regions, including the PRC, Hong Kong Special Administrative Region, Taiwan region, Switzerland, Egypt, South Korea, Thailand, Singapore, Australia, Malaysia, Vietnam, Russia, India, Brazil and South Africa.
With an accelerating trend of population aging in the PRC and the relevant countries and regions, the acquisition of Miacalcic will bring huge market opportunities to the Group and further enrich the product portfolio that paving the way for adding long-term growth potentials to the Company.
By order of the Board
China NT Pharma Group Company Limited Ng TitChairman
Hong Kong, 19 December 2016
As at the date of this announcement, the executive Directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Directors of the Company are Dr. Qian Wei and Mr. Ge Jianqiu; and the independent non-executive Directors of the Company are Mr. Yue Nien Martin Tang, Mr. Patrick Sun and Dr. Lap-Chee Tsui.